BioSpace News Archive

Virpax ® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock

PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.

AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received authorization from the Russian Health Ministry (MoH) to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001).

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug application to begin a Phase I trial of BMF-219,

Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the results of a three-part clinical study that further demonstrates the strong associations between a high MedWise Risk Score™ and poor health outcomes.

Croom Medical has produced over 20,000 Additive Implants as of September 2021 at its Additive Manufacturing center of excellence.

Rhaeos, Inc., a private medical device company focused on the care of patients with hydrocephalus, announced today it was awarded a $4 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Neurological Disorders and Stroke (NINDS).

Elite HRT, a leading force in hormone replacement therapy wellness, has just published guidance on how to approach this treatment.

Dalrada Corporation (OTCQB: DFCO, “Dalrada”) is excited to share information on the Company’s community outreach efforts that support free, on-site COVID-19 point-of-care tests at in-person events.

Inventiva announced a series of recruitments with a view to accelerate the development of its lead drug candidate lanifibranor for the treatment of NASH.